– The expanding partnership with Clinmark is another important step for us bringing PolTREG closer to the start of a Phase I/II clinical trial of the PreTREG diabetes therapy project.We are already co-operating with several centers for the clinical trial – said Prof. Piotr Trzonkowski, CEO and co-founder of PolTREG.
2023-02-13
PolTREG signs an agreement with Clinmark for clinical trials in PreTREG project
See other news
2026-01-21
Immuthera appoints Dr. Antionette Moran, Dr. Jason Gaglia, and Dr. Jeffrey Cohen, Renowned Endocrinologists, Diabetologists and Neuroscientist to the Scientific Advisory Board (SAB)
2026-01-12
Immuthera announces global exclusive license from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg platform for autoimmune and inflammatory diseases
2025-11-27
PolTREG published data in a prestigious scientific journal demonstrating the long-term effectiveness of TREG cell therapy, which can halt the development of type 1 diabetes in children
2025-11-14
World Diabetes Day. PolTREG is developing a therapy that can stop the development of type 1 diabetes in children.
2025-11-07
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
